ASCO 2022

June 3-7

The tests featured in this video are available in the United States. Availability outside of the U.S. differs by country.

Exact Sciences Showcases Breadth of Early Detection and Treatment Guidance Portfolio with Multiple Data Presentations at ASCO 2022

Read the Press Release

Supporting Patients at Every Step

Exact Sciences’ portfolio of products focuses on colorectal, breast, prostate, lung, and liver cancers. We also have a multi-cancer early detection (MCED) blood test in development to find more cancers at earlier stages, when it's most treatable.*

From earlier detection to treatment guidance and monitoring, we aim to offer a comprehensive suite of tests to enable personalized care across the cancer continuum.

Hereditary
Cancer

Screening

Prognosis & Therapy Guidance

Minimal Residual Disease

Recurrence
Monitoring

Therapy Selection

*Based on 5 year survival

PRECISION ONCOLOGY

A portfolio of genomic solutions that delivers actionable insights on treatment determination and therapy selection to inform personalized decisions.

We're defining a new approach to oncology genomics with our Precision Oncology portfolio.

Availability of these tests outside of the U.S. varies by country

Treatment
DETERMINATION

Therapy
Selection

innovation across the cancer continuum

Availability of these tests outside of the U.S. varies by country

Cologuard^® is an easy, effective, non-invasive colorectal cancer screening test for average risk adults 45 and older. Cologuard can be used at home and finds 92% of all cancers and 94% of Stage I and Stage II cancers.

MULTI-CANCER
‍EARLY DETECTION

When found early, cancer is often more effectively treated, enabling better outcomes for patients. Our goal is to integrate a blood test to screen for multiple types of cancer into routine medical care.

Liver cancer is the fastest growing cause of cancer-related death in the United States. The Oncoguard^® Liver solution offers a powerful combination of performance, accessibility, and adherence support for a streamlined approach to HCC detection.

The exact science
behind conquering cancer

Patient advocacy organizations are invited to learn more about Exact Sciences’ current portfolio, pipeline of tests, and how we aim to transform cancer care for patients – before, during, and after a cancer diagnosis. Our multi-cancer early detection and precision oncology teams will be available to share a comprehensive overview of our earlier cancer detection and treatment guidance programs, as well as our efforts to ensure patient voices from all backgrounds are kept at the forefront of our work. The event will conclude with a moderated discussion around strategies to raise the profile of innovative technologies that have the potential to improve the lives of patients.
‍
Date/time: Sunday, June 5, 6:45am-8:00am CT.
Note: This is an invitation only event.

ABSTRACTS of Interest

NSABP C-14: CORRECT-MRD II – Second colorectal cancer clinical validation study to predict recurrence using a circulating tumor DNA assay to detect minimal residual disease

Authors: Salem, M., et al.

Session: Gastrointestinal Cancer ‒ Colorectal and Anal

Poster Discussion: 8:00-11:00 a.m. CT

Abstract Number: TPS3632

Methylated DNA markers in early detection of lymphoma: Discovery, validation, and clinical pilot

Authors: Witzig, T., et al.

Session: Hematologic Malignancies ‒ Lymphoma and Chronic Lymphocytic Leukemia

Poster Discussion: 8:00-11:00 a.m. CT

Abstract Number: 7562

Comprehensive genomic profiling to identify gene alterations in DNA repair pathway across solid tumors

Authors: McDonnell, K., et al.

Session: Developmental Therapeutics ‒ Molecularly Targeted Agents and Tumor Biology

Poster Discussion: 8:00-11:00 a.m. CT

Abstract Number: 3124

Comprehensive whole-exome and transcriptome profiling to identify actionable alterations associated with response to PARP inhibitors in breast cancer

Authors: Dombrowski, S., et al.

Session: Breast Cancer ‒ Metastatic

Poster Discussion: 8:00-11:00 a.m. CT

Abstract Number: 1096

BRAF mutation classes and co-occurring mutations in NSCLC

Authors: Niu, J., et al.

Session: Lung Cancer ‒ Non-Small Cell Metastatic

Poster Discussion: 8:00-11:00 a.m. CT

Abstract Number: 9083

Characterization of time to diagnosis indicates shorter interval for screenable versus symptom-driven cancers

Authors: Gainullin, V., et al.

Session: Prevention, Risk Reduction, and Hereditary Cancer

Poster Discussion: 1:15-4:15 p.m. CT

Abstract Number: 10526

Comparison of Simulated Outcomes Between Stool- and Blood-Based Colorectal Cancer Screening Tests

Authors: Fendrick, A. M., et al.

Session: Prevention, Risk Reduction, and Hereditary Cancer

Poster Discussion: 1:15-4:15 p.m. CT

Abstract Number: 10529

Plasma methylated DNA markers of cutaneous melanoma: Association with PET/CT-positive disease.

Authors: Meves, A., et al.

Session: Melanoma/Skin Cancers

Poster Discussion: 3:15-6:15 p.m. CT

Abstract Number: 9567

Methylated DNA markers in urine aid in the selective identification of patients with prostate cancer as well as clinically significant pathology.

Authors: Shah, P., et al.

Session: Genitourinary Cancer ‒ Prostate, Testicular, and Penile

Poster Discussion: 3:15-6:15 p.m. CT

Abstract Number: 5091

Cost-effectiveness of mt-sDNA vs mailed FIT outreach for Medicare Advantage enrollees using the CRC-AIM microsimulation model

Authors: Bhatt, J., et al.

Abstract Number: e18827

Cost-effectiveness of waiving coinsurance for follow-up colonoscopy after a positive stool-based colorectal screening test in a Medicare population

Authors: Fendrick, A. M., et al.

Abstract Number: e13624

Modeling analysis of COVID 19-related delays in colorectal cancer screening on simulated clinical outcomes

Authors: Miller-Wilson, L. et al.

Abstract Number: e13631

Plasma methylated DNA markers detect recurrence and response to therapy in colorectal cancer

Authors: Zhu, M., et al.

Abstract Number: e15567